CH BIOTECH SER(08037) and Shenzhen BGI Genomics Technology have entered into a strategic cooperation framework agreement.

CH BIOTECH SER (08037) announced on February 25, 2025, that the company has entered into a strategic cooperation framework agreement with Shenzhen BGI Genomics Technology Co., Ltd. (Shenzhen Huada Technology): (1) The two parties will jointly conduct clinical research based on BNCT therapy to promote the clinical application and academic promotion of BNCT technology in China. (2) The two parties will jointly carry out academic research on a new targeted CD20 CAR-T therapy method, explore the clinical application and commercialization pathways, and promote the benefits of this new treatment method to a wider range of suitable patient populations. (3) Shenzhen Huada Technology will serve as a priority partner, providing the company with post-treatment testing products and solutions for monitoring and evaluating the effects of treatment on patients and for long-term follow-up. (4) The two parties will form a closed loop in the fields of precise screening and diagnosis of tumors, CAR-T and BNCT therapies, and post-treatment monitoring, promoting the improvement of the overall level of comprehensive tumor treatment. The goal is to provide comprehensive, all-round diagnosis and treatment services for cancer patients, improving their survival rates and quality of life. Shenzhen Huada Technology will leverage its advantages in multi-disciplinary research and genetic testing to provide technical support such as tumor genetic testing and pathology testing to the company. The company will prioritize Shenzhen Huada Technology's technical and product solutions in the relevant fields. (5) The two parties will jointly organize or participate in academic conferences, seminars, and other activities related to BNCT therapy, domestically and internationally, to share research results and clinical experiences and enhance their academic influence. They will also cooperate in education and training programs related to BNCT therapy and other collaborative content to cultivate professional talents and raise the overall level of the industry. Huada and the company have complementary advantages in the fields of precise tumor diagnosis, treatment, and technical research and development, and are willing to cooperate based on the principles of equality, mutual benefit, win-win cooperation, and mutual development. As priority strategic partners in each other's fields, they will rely on their respective resources and strengths to carry out all-round cooperation in innovative solutions for the full-cycle management of malignant tumors, including but not limited to academic exchanges, joint research, technology transfer, and diagnosis and treatment services, to jointly promote the development of cancer prevention and control, benefiting more patients and families, effectively reducing the incidence and mortality of malignant tumors, and working together to achieve the goal of a healthy China. Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd. (Pengbo (Hainan), an indirectly wholly-owned subsidiary of the company) has signed an investment intent agreement with Shenzhen Huada Songhe Shengke No. 1 Private Equity Venture Capital Fund Partnership Enterprise (Limited Partnership) (Investor) regarding the investment in Pengbo (Hainan). This round of investment by the Investor in Pengbo (Hainan) will see an investment of RMB 20-30 million based on a pre-investment valuation of RMB 450 million for Pengbo (Hainan), to subscribe for additional registered capital in Pengbo (Hainan). Following this round of investment, the exact amount and percentage of equity obtained by the Investor will be as stipulated in the formal transaction documents. The Investor is mainly engaged in private equity venture investment business, focusing on life sciences, biotechnology, and related fields, by investing in promising start-ups or projects to support the development of relevant enterprises. Pengbo (Hainan) mainly provides Boron Neutron Capture Therapy (BNCT). The Hainan Boao BNCT Boron Neutron Treatment Center is scheduled to open in the fourth quarter of 2025. If the Investor's planned investment in Pengbo (Hainan) is realized, it will signify the Investor's confidence in the future development of the center and the Group's commitment to providing BNCT treatment services to cancer patients in need. This will enhance Pengbo (Hainan)'s corporate image and strengthen its capital base.